GLIPIZIDE, a sulphonyl-cyclohexylurea derivative, was introduced in 1971. It was found to be a hypolycaemic of great potency, short action and low toxicity. This report is concerned with the results following treatment for one year with the drug in a diabetic clinic in Belfast. The study particularly examined the effect of the drug on patients of differing degrees of obesity and also examined the effect of the drug in patients who had been on previous sulphonylurea therapy.
PATIENTS AND METHODS Diabetics admitted to this study were patients in whom the disease was discovered after the age of 40 and who were not ketotic. All were treated as outpatients and continued their usual life. Details of the population studied are shown in Table I (Cahill et al 1976) . Microvascular complications are problems both in juvenile and maturity onset patients. While dietary treatment may achieve normal glucose tolerance in many maturity onset patients a significant number lack the discipline and motivation required for the success of this regime. Our study demonstrates that glipizide, a second generation sulphonylurea significantly lowers blood glucose levels. As many of these patients had failed to improve on dietary treatment alone it is unlikely that the decrease in blood glucose could be explained by dietary compliance over the year of glipizide treatment. That improved dietary compliance is improbable is also suggested by the fact that no group lost weight over the period of study. Our patients had no significant side effects. The study thus confirms the evidence of previous trials on the efficacy of glipizide. A preliminary multicentre trial on 1064 diabetic patients reported by Emanueli et al 1972 showed it to give favourable control in 80 per cent of maturity onset diabetics when used in doses of 2.5 mgs. It was considered to have equivalent activity to glibenclamide. A further multicentre trial co-ordinated by Lahon and Mann (1973) was performed on 177 maturity onset diabetics to compare glipizide with glibenclamide, chlorpropamide and phenformin. Little difference between the efficacy of the various compounds was seen. Side effects were minimal with glipizide and the doses used with safety were increased to 30 mg/day.
Pharmacological studies summarized by Artini et al (1973 ), Tomassia (1975 , Domingo-Gutierrez and Fernandez-Cruz (1975) show that glipizide, unlike glibenclamide is rapidly absorbed and produces an early insulin release at 30-60 min returning to basal levels by 90 min. It would be reasonable to conclude that clinical experience with the two drugs might be different; whereas glibenclamide could be given in one dose daily, glipizide might need divided dosage. Under clinical conditions the experience of Person (1973) in 19 patients, was that in patients requiring 10 mg or less of glipizide per day the drug could be given in one morning dose, whereas a daily dose of over 10mg was given in two doses morning and evening. Our practical experience was similar. Long-term results over a four year period on 72 patients formed the basis of the conclusion of Perodi and Caputo (1975) that the hypoglycaemic action of glipizide did not decrease with time and the drug was non-toxic. Another long-term study by Woodruffe (1975) included 22 out of 28 patients who had been satisfactorily treated for over 12 months. Lebouc and Derot (1975) evaluating 50 maturity onset diabetics over several months, 9 completing one year's treatment confirmed its effectiveness on reducing blood sugars. In this study weight gain on glipizide unlike most sulphonylureas was minimal which is similar to our experience. Alexander et al (1975) gave preliminary findings in 23 diabetics who had been placed on a year trial which was not completed at that date. They thought it effective but not giving better results that other sulphoonylureas. However in our study an important feature was the improvement in blood glucose in patients previously treated with sulphonylureas. The incidence of of failure of sulphonylurea therapy has been reported as up to 5 per cent per year (Williams and Porte 1974) .Our investigation would suggest that glipizide may be of value in patients when treatment has failed with other forms of sulphonylurea therapy.
In conclusion our study which is comparable to other long term trials confirms that glinizide is a safe effective oral agent and without significant effects on the body weight. SUMMARY Fifty-two patients with maturity onset diabetes were treated with glipizide (Minodiab) under the conditions of routine practice of a dibetic clinic. Blood sugar control was assessed after completion of one year's treatment. Percentage ideal weights were compared at the beginning and the end of the period. Patients were subdivided into grossly obese, overweight, normal and underweight groups. Improvement in the mean fasting and post-prandial blood sugars was observed in all groups. Significant improvement over previous therapy was observed. In conclusion glipizide in doses from 5-20 mg appeared an effective and non-toxic sulphonylurea under the conditions of clinical practice. Our findings would confirm long term trials elsewhere.
